MEMO1 and breast carcinoma: MEMO1 (human nomenclature used throughout) was originally discovered through its ability to bind one of these ‘docking’ sites on the erythroblastic oncogene B (ERBB2) receptor within a human epithelial breast cancer cell line [1] (Figure 1A).